TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE B-

NCT04728893: A Phase 2 Study to Evaluate the Efficacy and Safety of MK-1026 in Participants With Hematologic Malignancies

Sponsor: Merck Sharp & Dohme LLC · Phase: PHASE2 · Area: ONCOLOGY · Target Enrollment: 490 pts

Competing Trials Overlap

7 Active Trials

Excess Burn Exposure

$554,400

Rescue Site Savings

+$369,600

Unlock Full NCT04728893 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT04728893 Rescue Dossier →